CHM-2101 CAR-T cells
Phase 2Cell therapy
CHM-2101 CAR-T cells is one of 9 biologic programs targeting T Cell Therapy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in T Cell Therapy
#DrugCompanyPhaseTrials
1Fludara
SanofiApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Venclexta
AbbViePhase 1
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 1
GM-CSF
YY-mAbs Therapeutics
Phase 1
Allogeneic Γδ T Cells
PPeking University Third Hospital
Phase 2
Allogenic CD19-CAR-γδT Cell
Novo NordiskPhase 2
CHM-2101 CAR-T cells
CChimeric Therapeutics
Phase 2
T-Cell Therapy
HH. Lee Moffitt Cancer Center and Research Institute
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CHM-2101 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- CChimeric Therapeutics